Gerstner, E. R., Zhang, Z., Fink, J. R., Muzi, M., Hanna, L., Greco, E., … Mankoff, D. A. (2015). ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI. In Journal of Clinical Oncology (Vol. 33, pp. 2024–2024). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.2024

Gerstner, Elizabeth Robins, Zheng Zhang, James R. Fink, Mark Muzi, Lucy Hanna, Erin Greco, Akiva Mintz, et al. “ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI.” In Journal of Clinical Oncology, 33:2024–2024. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2024.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, et al. ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2024–2024.

Gerstner, Elizabeth Robins, et al. “ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 2024–2024. Crossref, doi:10.1200/jco.2015.33.15_suppl.2024.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Mintz A, Kostakoglu L, Eikman EA, Prah M, Schmainda KM, Sorensen GA, Barboriak D, Mankoff DA. ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2024–2024.